UTHealth Houston is currently recruiting participants for a study exploring the potential of psilocybin, a compound found in “magic mushrooms,” to treat individuals with treatment-resistant depression.
Dried psilocybin mushrooms (photo credit: Rich Townsend/Getty Images).
The study, conducted by the Center of Excellence on Mood Disorders, is part of a global multi-center initiative sponsored by COMPASS Pathways. The trial will involve a single administration of either 25 mg of psilocybin or a placebo. Participants will be closely monitored and supported by specially trained therapists throughout the process. These therapists will guide them before, during, and after the psilocybin session to ensure a safe and comfortable experience.
A key requirement for participation is that all individuals on antidepressants must taper off their medication 3 to 6 weeks before the study’s baseline phase. The study team will assist with this tapering process to ensure patient safety.
Continue reading
While approving 121 new store applications, the DCC ruled that 47 of these retailers cannot open in Franklin, Cuyahoga, or Hamilton counties, which encompass Columbus, Cleveland, and Cincinnati. The DCC determined that these areas already have adequate retail presence, and no new licenses will be approved for the foreseeable future.
“Our 2023-2024 campaign has concluded and we did not meet the requirements to get on the ballot”, said Kind Idaho in a social media post. The group was referring to a medical marijuana initiative they were hoping to place on this year’s ballot, but fell short of the required signatures. “Thank you to everyone that signed, donated, volunteered!”
